Saturday 17 October 2026
Export BCYC’s income statement to Excel — free account
Bicycle Therapeutics PLC Sponsored ADR
BCYC Healthcare Biotechnology
Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024. In the quarter to June 2026, revenue fell 78.5%, EPS grew 36.8% and free cash flow grew 32.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
3.46
0.14
−3.89%
Follow BCYC
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 3 | 1 | 4 | 2 | 4 | 4 | 2 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 2.78 | 1.81 | 6.85 | 2.66 | 0.50 | 2.38 | 0.99 |
P/S ratio |
— | 0.93 | 0.93 | 7.55 | 33.08 | 130.42 | 61.52 | 24.33 | 23.10 | 6.76 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 1.50 | 0.38 | 6.85 | 1.69 | 6.09 | 2.54 | 2.21 | 7.20 | 5.27 |
P/Operating CF |
— | (1.92) | (1.92) | (21.17) | (20.68) | (146.19) | (29.36) | (13.88) | (86.73) | (25.35) |
Beneish M-Score |
— | — | 0.75 | (2.32) | (3.07) | (2.59) | (2.09) | (3.12) | (2.09) | (1.37) |
P/B ratio |
— | 0.00 | 0.00 | 1.12 | 3.60 | 4.41 | 3.29 | 1.77 | 1.03 | 0.80 |
Price to Tangible BV |
— | 0.00 | 0.00 | 1.12 | 3.60 | 4.41 | 3.29 | 1.77 | 1.03 | 0.80 |
EV/Sales |
— | (4.61) | (4.61) | 1.01 | 21.47 | 95.67 | 40.39 | 6.13 | (1.30) | (1.61) |
EV/EBITDA |
— | 2.31 | 2.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.23 | 0.48 |
EV/Operating CF |
— | 2.06 | 2.06 | (0.49) | (12.54) | (75.65) | (6.78) | (2.73) | 0.28 | 0.47 |
EV/FCF |
— | 1.95 | 1.95 | (0.46) | (11.75) | (66.52) | (5.56) | (2.60) | 0.28 | 0.46 |
Quick Ratio |
2.83 | 7.48 | 8.37 | 11.25 | 6.51 | 12.43 | 6.76 | 7.92 | 13.61 | 11.65 |
Current Ratio |
2.96 | 7.57 | 8.60 | 11.81 | 6.73 | 12.65 | 6.92 | 8.08 | 13.81 | 11.98 |
Net Debt/EBITDA |
0.71 | 4.26 | 3.01 | 3.59 | 2.40 | 6.37 | 2.73 | 2.70 | 4.34 | 2.61 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.14% | 9.00% | 6.23% | 7.38% | 5.16% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | 0.15 | 0.09 | 0.11 | 0.08 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.05 | 0.09 | 0.14 | 0.08 | 0.04 | 0.03 | 0.05 | 0.05 | 0.09 |
Operating CF/Net income |
0.83 | 0.09 | 1.19 | 0.93 | 0.35 | 0.22 | 0.76 | 0.34 | 0.97 | 1.14 |
Capex/Depreciation |
0.00 | (3.35) | (1.67) | (1.62) | (0.94) | (1.44) | (5.15) | (0.45) | (0.17) | (0.37) |
Interest Coverage |
(3,373.35) | (324.26) | (128.90) | (32.17) | (113.70) | (21.99) | (34.88) | (58.21) | (121.31) | (1,199.34) |
| 33.37% | 40.16% | 37.34% | (261.92%) | (54.08%) | (30.25%) | (36.53%) | (56.31%) | (29.04%) | (31.21%) | |
| (31.48%) | (37.88%) | (28.07%) | (31.91%) | (37.60%) | (20.85%) | (25.32%) | (35.92%) | (21.78%) | (26.15%) | |
ROIC |
0.00% | 0.00% | 0.00% | (704.84%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(169.01%) | (25.64%) | (31.36%) | (31.36%) | (37.81%) | (15.71%) | (33.63%) | (35.64%) | (19.41%) | (34.65%) |
Average Days of Receivables |
0.00 | 531.73 | 578.65 | 188.97 | 514.06 | 371.65 | 535.20 | 325.26 | 368.91 | 178.99 |
Research and Development Expense of Revenue |
0.00% | 576.02% | 290.93% | 185.06% | 319.05% | 383.69% | 564.26% | 580.13% | 490.34% | 331.03% |
Selling, General and Administrative Expense of Revenue |
0.00% | 311.02% | 113.80% | 105.50% | 281.05% | 277.29% | 342.30% | 224.00% | 204.62% | 109.34% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 25.00% | 14.34% | 22.34% | 62.69% | 103.30% | 185.16% | 120.39% | 107.95% | 54.37% |
Graham Net Nets |
— | (8.28) | (8.28) | 0.84 | 0.26 | 0.21 | 0.26 | 0.51 | 0.94 | 1.17 |
Graham Number |
— | 0.00 | 422.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (426.67%) | (426.67%) | (105.80%) | (14.76%) | (4.42%) | (12.67%) | (27.82%) | (20.57%) | (44.63%) |
Free Cash Flow Yield |
— | (253.26%) | (253.26%) | (28.96%) | (5.53%) | (1.10%) | (11.81%) | (9.68%) | (20.37%) | (51.38%) |
Revenue per Share |
0.00 | 6.18 | 16.26 | 1.25 | 0.54 | 0.47 | 0.49 | 0.76 | 0.61 | 1.05 |
Operating CF per Share |
(0.54) | (4.25) | (59.42) | (2.59) | (0.93) | (0.59) | (2.90) | (1.70) | (2.83) | (3.60) |
Capex per Share |
0.00 | (3.34) | (2.70) | (0.14) | (0.06) | (0.08) | (0.64) | (0.08) | (0.02) | (0.03) |
Free Cash Flow per Share |
(0.54) | (7.59) | (62.12) | (2.73) | (0.99) | (0.67) | (3.54) | (1.79) | (2.85) | (3.64) |
Cash per Share |
0.45 | 203.13 | 144.41 | 8.34 | 7.10 | 17.50 | 11.43 | 14.79 | 15.11 | 9.07 |
Shareholders Equity per Share |
0.38 | (141.65) | (159.09) | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | 13.62 | 8.80 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.38 | (141.65) | (159.09) | 8.44 | 4.99 | 13.82 | 9.13 | 10.42 | 13.62 | 8.80 |
Free Cash Flow |
(11.27) | (2.53) | (27.26) | (30.17) | (18.99) | (16.82) | (105.10) | (63.56) | (165.96) | (252.02) |
Working Capital |
7.48 | 62.06 | 67.84 | 95.33 | 132.59 | 422.32 | 316.04 | 492.33 | 861.38 | 625.90 |
Capital Expenditures |
(0.24) | (1.11) | (1.19) | (1.55) | (1.20) | (2.03) | (18.99) | (2.93) | (1.23) | (2.35) |
Net Current Asset Value |
7.48 | (49.67) | (74.68) | 87.15 | 90.03 | 325.02 | 229.56 | 337.46 | 764.80 | 575.27 |
EV/EBIT |
— | 2.23 | 2.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.47 |
Capex to Sales |
— | 0.54 | 0.17 | 0.11 | 0.12 | 0.17 | 1.31 | 0.11 | 0.04 | 0.03 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.52 | 0.24 | 0.39 | 0.42 | 0.55 | 0.45 | 0.19 | 0.45 | 0.75 | 1.07 |
Cash ROIC |
(64.66%) | (12.34%) | 422.96% | (16.17%) | (7.72%) | (2.06%) | (16.42%) | (6.85%) | (9.92%) | (20.36%) |
Accounts Receivable Turnover |
0.00 | 0.94 | 1.00 | 1.50 | 0.95 | 0.88 | 0.87 | 1.19 | 1.18 | 2.04 |
Accounts Payable Turnover |
0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | — | — | — | 0.00 | — | — | — |
Average Days of Payables |
2,553.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | — | — | — | 0.00 | — | — | — |
Average Receivables |
2.19 | 2.19 | 7.16 | 9.23 | 10.89 | 13.27 | 16.56 | 22.62 | 29.85 | 35.62 |
Average Payables |
1.97 | 1.97 | 1.98 | 1.92 | 1.66 | 2.04 | 4.60 | 9.76 | 14.42 | 12.73 |
Average Assets |
42.92 | 42.92 | 77.81 | 95.91 | 135.67 | 320.47 | 445.20 | 502.98 | 776.11 | 837.23 |
Average Common Equity |
(40.49) | (40.49) | (58.50) | 11.69 | 94.33 | 220.86 | 308.52 | 320.86 | 582.00 | 701.52 |
Columns are period end dates